5 mg Tirzepatide: What It Does, What It Costs, When to Move On

What to expect on side effects

A second, usually milder wave of nausea in the week after the increase. Constipation often appears here and tends to persist rather than fade.

When to move up — and when not to

Many people could stop climbing here and get an excellent result. Escalate if loss has stalled or appetite suppression is fading, not because the calendar says so.

What every program charges at 5 mg

Flat-rate programs show the same figure here as at 2.5 mg. Dose-scaled programs do not — and this is where that difference becomes visible.

What 5 mg does clinically

5 mg is the first dose intended to do therapeutic work. In the SURMOUNT-1 program it was one of three studied maintenance arms, and it produced meaningful mean weight reduction — less than the higher arms, but far from nothing. A minority of patients hold here for the whole course because the response is adequate and tolerance is limiting.

Who maintains at this dose

Patients who respond strongly early, patients with significant gastrointestinal sensitivity, and patients whose clinician prefers the lowest effective dose.

What 5 mg costs across the market

At 5 mg the market splits cleanly. 19 tracked programs charge the same here as at the starter dose; 4 charge more. That split is worth $349 a month between the cheapest and dearest option at this exact strength, or $4,188 over a year of holding it.

Normalized per milligram of active drug, 5 mg weekly is 20 mg a month. At the cheapest tracked rate that is about $9.95 per milligram; at the dearest, about $27.40. On a flat-rate program this figure falls every time you escalate, which is the arithmetic reason flat pricing wins over a full course.

Side effects at this step

Adverse effects on tirzepatide cluster in the days after any increase rather than at any particular strength, and they are dose-related in frequency: nausea, diarrhea, constipation and vomiting all rise as the dose does. If the step to 5 mg produces nausea that limits what you eat, holding this strength for a further four weeks is the standard response — not climbing faster and not stopping. The full side-effect reference covers each one with reported frequencies and red flags.

Before you price this dose

Check whether your program's advertised figure applies here or only at the starter dose. That single question is worth $4,188 a year between the extremes of this table, and it is the reason this site prices every strength separately rather than publishing one number.

5 mg tirzepatide: the week-by-week experience

The first week at 5 mg is the adaptation week: adverse effects cluster in the two to four days after any increase, so most of what you feel in the days after the step is the step rather than the drug. Weeks two through four are the assessment window — if appetite control is adequate and side effects have faded, this is a dose you could hold.

The decision at the end of these four weeks is genuinely open: hold 5 mg, repeat it for another cycle, or step up to 7.5 mg. Holding a dose that is working is not under-treatment, and repeating a dose that is not tolerated is not failure.

Is 5 mg tirzepatide enough?

Enough is defined by your response, not by the ceiling. If appetite is manageable, weight is moving at a rate you and your prescriber are content with, and side effects have settled into background noise, 5 mg is enough. The evidence for escalating beyond a working dose is weaker than most patients assume, and gastrointestinal adverse events continue to rise with dose whether or not the extra effect materializes for you.

5 mg tirzepatide pricing: why the spread is this wide

At this strength the tracked market runs $199 to $548 per month — a spread of $349, or $4,188 across a year of holding it. Same molecule, same category of licensed pharmacy. 19 of the 23 programs priced at this tier hold the same rate they charge at the starter dose; the rest charge more here than they advertise on their homepage.

If your program is one that reprices with dose, the figure you were quoted at intake described 2.5 mg and not this row. Ask what changes at 5 mg before you enrol, not after you arrive here.

5 mg tirzepatide and the twelve-month picture

Holding 5 mg for a full year after a standard two-month titration costs from $2,388 at the cheapest tracked route. Since the withdrawal evidence shows substantial regain after stopping, the more honest horizon is three years, which puts the same route near $7,164. Run your own numbers at this strength with the projector before committing to any prepaid term.

Moving on from 5 mg

Step up only when 5 mg has stopped delivering and you are tolerating it well; hold when it is working; step down when it is not tolerated. The next rung is 7.5 mg, at least four weeks away. Whatever the direction, the interval between changes is at least four weeks, and a repeated cycle is ordinary practice rather than a setback.

5 mg tirzepatide: the gap between advertised and actual

Advertised prices describe 2.5 mg. This table shows what the same programs charge at 5 mg, and the difference is what a homepage figure conceals from anyone who will not stay at the starter dose — which is everybody.

Programs showing a zero increase hold one price at every strength. Those are the routes whose advertised figure is also their maintenance figure, and the reason flat pricing is worth paying a higher entry price for if you expect to escalate.

5 mg tirzepatide: questions for your prescriber at this step

1. Do you expect 5 mg to be my maintenance dose, or a step on the way to something higher?
2. What would make you hold or reduce rather than increase at the next review?
3. What side effects at this strength would you want to hear about immediately rather than at the next check-in?
4. Do any of my other medications need reviewing now that I am at this dose?
5. If I tolerate this well, what is the case for going higher — and what is the case against?

The last one matters most and is asked least. Escalation is frequently treated as automatic, when the evidence for going beyond a dose that is already working is weaker than most patients assume and the gastrointestinal cost is not.

5 mg tirzepatide: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

5 mg tirzepatide: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

5 mg tirzepatide: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.